Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HDSI ~ HDS International Corp. due diligence report
$HDSI recent news/filings
## source: finance.yahoo.com
Mon, 11 Jan 2016 16:36:31 GMT ~ HDS International Retains Counsel to Seek Recovery for Shareholders
[Marketwired] - HDS International Corp. and CMG Holdings Group, Inc. and : CMG Holdings Group, Inc.'s majority-owned subsidiary, HDS International Corp., and SirenGPS, Inc. have retained the services of the law firm Elias, ...
read full: http://finance.yahoo.com/news/hds-international-retains-counsel-seek-163631603.html
*********************************************************
Tue, 08 Dec 2015 18:11:57 GMT ~ HDS INTERNATIONAL CORP. Financials
read full: http://finance.yahoo.com/q/is?s=hdsi
*********************************************************
Fri, 13 Nov 2015 11:02:59 GMT ~ HDS INTERNATIONAL CORP. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F
read full: http://biz.yahoo.com/e/151113/hdsi8-k_a.html
*********************************************************
Tue, 10 Nov 2015 18:27:14 GMT ~ HDS INTERNATIONAL CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fin
read full: http://biz.yahoo.com/e/151110/hdsi8-k.html
*********************************************************
Wed, 08 Jul 2015 17:24:40 GMT ~ HDS INTERNATIONAL CORP. Files SEC form 8-K, Regulation FD Disclosure
read full: http://biz.yahoo.com/e/150708/hdsi8-k.html
*********************************************************
$HDSI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$HDSI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/HDSI/company-info
Ticker: $HDSI
OTC Market Place: OTC Pink Limited
CIK code: 0001454742
Company name: HDS International Corp.
Company website: http://www.hdsicorp.com
Incorporated In: NV, USA
Business Description: HDS International Corp., based in Providence, RI, is a green technologycompany providing carbon capture and sequestration solutions, as well as industrial, all naturalocean-based algae farming solutions for the production of renewable, sustainable, andeconomically viable biofuels, bioproducts, and carbon elimination. Our licensed technologiesprovide us with an attractive strategic position and competitive advantages within our markets,which include renewable energy and environmental and eco-sustainability.Less >>
$HDSI share structure
## source: otcmarkets.com
Market Value: $384,400 a/o Jan 11, 2016
Shares Outstanding: 1,922,000,000 a/o Mar 24, 2015
Float: 91,980,000 a/o Aug 16, 2011
Authorized Shares: 2,000,000,000 a/o Aug 16, 2011
Par Value: 0.001
$HDSI extra dd links
Company name: HDS International Corp.
Company website: http://www.hdsicorp.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=HDSI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=HDSI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=HDSI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/HDSI/news - http://finance.yahoo.com/q/h?s=HDSI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/HDSI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/HDSI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=HDSI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/HDSI
DTCC (dtcc.com): http://search2.dtcc.com/?q=HDS+International+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=HDS+International+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=HDS+International+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.hdsicorp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.hdsicorp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.hdsicorp.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/HDSI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001454742&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/HDSI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/HDSI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=HDSI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=HDSI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/HDSI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=HDSI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=HDSI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=HDSI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=HDSI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=HDSI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/HDSI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=HDSI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/HDSI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=HDSI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/HDSI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/HDSI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/HDSI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/HDSI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/HDSI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=HDSI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=HDSI
$GLDG ~ Golden Global Corp. due diligence report
$GLDG recent news/filings
## source: finance.yahoo.com
Mon, 04 Jan 2016 22:14:55 GMT ~ GOLDEN GLOBAL CORP. Files SEC form 8-K, Change in Directors or Principal Officers
read full: http://biz.yahoo.com/e/160104/gldg8-k.html
*********************************************************
Tue, 08 Dec 2015 18:11:19 GMT ~ GOLDEN GLOBAL CORP. Financials
read full: http://finance.yahoo.com/q/is?s=gldg
*********************************************************
Tue, 08 Dec 2015 17:15:18 GMT ~ Golden Global Corp (GLDG) Finalizes Endorsement Deals for Combo Hitter
[Marketwired] - Golden Global Corp. , along with its wholly owned subsidiary Combo Hitter, LLC., is excited to announce today the signing of two 5-year endorsement deals with UFC stars Stipe Miocic and Jessica "Evil" ...
read full: http://finance.yahoo.com/news/golden-global-corp-gldg-finalizes-171518980.html
*********************************************************
Mon, 16 Nov 2015 15:00:00 GMT ~ Golden Global Corp (GLDG) Releases Letter to Shareholders on Post Combo Hitter Acquisition Updates
[Marketwired] - In an open letter to shareholders, the President and CEO of GLDG , Robert Leyne Lee, made the following statements:
read full: http://finance.yahoo.com/news/golden-global-corp-gldg-releases-150000751.html
*********************************************************
Mon, 02 Nov 2015 17:26:16 GMT ~ GOLDEN GLOBAL CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur
read full: http://biz.yahoo.com/e/151102/gldg8-k.html
*********************************************************
$GLDG charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$GLDG company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/GLDG/company-info
Ticker: $GLDG
OTC Market Place: OTC Pink Limited
CIK code: 0001502555
Company name: Golden Global Corp.
Company website: http://www.goldenglobalcorp.com
Incorporated In: NV, USA
Business Description: Fitness services, innovative equipment sales and franchisingThe company was founded in 2009 and recently moved away from the gold mining business. GLDG acquired its wholly owned subsidiary,Comb Hitter, LLC, through a stock swap finalized on October 12, 2015 and expects to be revenue producing in 2016.Combo Hitter has made an impressive impact on the Fitness industry and it's soon to be patented one of a kind \"Combo punching /kicking bag\" is attracting buyers in both the pubic and private sectors. World renowned UFC Fighting Champion, Brad Kholer, is the sole inventor of the Combo Hitter who still leads the team in moving the company ahead in becoming a household name in the fast growing fitness industry. Get fit now go to www.combohitter.com.Less >>
$GLDG share structure
## source: otcmarkets.com
Market Value: $7,039 a/o Jan 04, 2016
Shares Outstanding: 28,154,125 a/o May 11, 2015
Float: 6,500,000 a/o Dec 23, 2014
Authorized Shares: 4,500,000,000 a/o Dec 01, 2014
Par Value: Not Available
$GLDG extra dd links
Company name: Golden Global Corp.
Company website: http://www.goldenglobalcorp.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GLDG+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GLDG+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GLDG+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/news - http://finance.yahoo.com/q/h?s=GLDG+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GLDG/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GLDG+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GLDG
DTCC (dtcc.com): http://search2.dtcc.com/?q=Golden+Global+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Golden+Global+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Golden+Global+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.goldenglobalcorp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.goldenglobalcorp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.goldenglobalcorp.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GLDG
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001502555&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GLDG&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GLDG
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GLDG+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GLDG+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GLDG
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GLDG
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GLDG+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GLDG/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GLDG+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GLDG.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GLDG
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GLDG
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GLDG
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GLDG:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GLDG
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GLDG
$GLDG ~ Golden Global Corp. due diligence report
$GLDG recent news/filings
## source: finance.yahoo.com
Mon, 04 Jan 2016 22:14:55 GMT ~ GOLDEN GLOBAL CORP. Files SEC form 8-K, Change in Directors or Principal Officers
read full: http://biz.yahoo.com/e/160104/gldg8-k.html
*********************************************************
Tue, 08 Dec 2015 18:11:19 GMT ~ GOLDEN GLOBAL CORP. Financials
read full: http://finance.yahoo.com/q/is?s=gldg
*********************************************************
Tue, 08 Dec 2015 17:15:18 GMT ~ Golden Global Corp (GLDG) Finalizes Endorsement Deals for Combo Hitter
[Marketwired] - Golden Global Corp. , along with its wholly owned subsidiary Combo Hitter, LLC., is excited to announce today the signing of two 5-year endorsement deals with UFC stars Stipe Miocic and Jessica "Evil" ...
read full: http://finance.yahoo.com/news/golden-global-corp-gldg-finalizes-171518980.html
*********************************************************
Mon, 16 Nov 2015 15:00:00 GMT ~ Golden Global Corp (GLDG) Releases Letter to Shareholders on Post Combo Hitter Acquisition Updates
[Marketwired] - In an open letter to shareholders, the President and CEO of GLDG , Robert Leyne Lee, made the following statements:
read full: http://finance.yahoo.com/news/golden-global-corp-gldg-releases-150000751.html
*********************************************************
Mon, 02 Nov 2015 17:26:16 GMT ~ GOLDEN GLOBAL CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur
read full: http://biz.yahoo.com/e/151102/gldg8-k.html
*********************************************************
$GLDG charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$GLDG company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/GLDG/company-info
Ticker: $GLDG
OTC Market Place: OTC Pink Limited
CIK code: 0001502555
Company name: Golden Global Corp.
Company website: http://www.goldenglobalcorp.com
Incorporated In: NV, USA
Business Description: Fitness services, innovative equipment sales and franchisingThe company was founded in 2009 and recently moved away from the gold mining business. GLDG acquired its wholly owned subsidiary,Comb Hitter, LLC, through a stock swap finalized on October 12, 2015 and expects to be revenue producing in 2016.Combo Hitter has made an impressive impact on the Fitness industry and it's soon to be patented one of a kind \"Combo punching /kicking bag\" is attracting buyers in both the pubic and private sectors. World renowned UFC Fighting Champion, Brad Kholer, is the sole inventor of the Combo Hitter who still leads the team in moving the company ahead in becoming a household name in the fast growing fitness industry. Get fit now go to www.combohitter.com.Less >>
$GLDG share structure
## source: otcmarkets.com
Market Value: $7,039 a/o Jan 04, 2016
Shares Outstanding: 28,154,125 a/o May 11, 2015
Float: 6,500,000 a/o Dec 23, 2014
Authorized Shares: 4,500,000,000 a/o Dec 01, 2014
Par Value: Not Available
$GLDG extra dd links
Company name: Golden Global Corp.
Company website: http://www.goldenglobalcorp.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GLDG+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GLDG+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GLDG+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/news - http://finance.yahoo.com/q/h?s=GLDG+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GLDG/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GLDG+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GLDG
DTCC (dtcc.com): http://search2.dtcc.com/?q=Golden+Global+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Golden+Global+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Golden+Global+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.goldenglobalcorp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.goldenglobalcorp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.goldenglobalcorp.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GLDG
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001502555&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GLDG&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GLDG
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GLDG+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GLDG+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GLDG
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GLDG
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GLDG+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GLDG/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GLDG+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GLDG.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GLDG
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GLDG/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GLDG/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GLDG
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GLDG
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GLDG:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GLDG
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GLDG
$FONU ~ FONU2 Inc. due diligence report
$FONU recent news/filings
## source: finance.yahoo.com
Fri, 08 Jan 2016 22:05:51 GMT ~ FONU2 INC. Files SEC form 8-K, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obli
read full: http://biz.yahoo.com/e/160108/fonu8-k.html
*********************************************************
Fri, 18 Dec 2015 21:20:27 GMT ~ FONU2 INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
read full: http://biz.yahoo.com/e/151218/fonu8-k.html
*********************************************************
Fri, 11 Dec 2015 21:03:47 GMT ~ FONU2 INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
read full: http://biz.yahoo.com/e/151211/fonu8-k.html
*********************************************************
Tue, 08 Dec 2015 18:15:38 GMT ~ FONU2 INC. Financials
read full: http://finance.yahoo.com/q/is?s=fonu
*********************************************************
Fri, 04 Dec 2015 21:59:53 GMT ~ FONU2 INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
read full: http://biz.yahoo.com/e/151204/fonu8-k.html
*********************************************************
$FONU charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$FONU company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/FONU/company-info
Ticker: $FONU
OTC Market Place: OTCQB
CIK code: 0001168325
Company name: FONU2 Inc.
Company website: http://www.fonu2.com
Incorporated In: NV, USA
Business Description: FONU2 is a film production and social commerce company that is developing a precision sales and marketing platform that integrates into the social media networks. The Fonu2 platform offers members list, buy, sell, and trade services locally in any neighborhood and anywhere in the world. Fonu2 is a Georgia, U.S. based film production company. Building on the business models of early Hollywood with a modern twist, we are in the process of designing and constructing a fully integrated film production facility that will enable efficiencies of scale and eliminate traditional waste. The Company is focusing on feature film projects that can be filmed on the Company?s property, or surrounding locations, to minimize costs and maximize efficiencies. Located in bucolic Coastal Georgia, we are building a true public/private partnership that will create permanent jobs.Less >>
$FONU share structure
## source: otcmarkets.com
Market Value: $84,769 a/o Jan 11, 2016
Shares Outstanding: 847,689,235 a/o Dec 11, 2015
Float: 34,650,040 a/o Apr 22, 2015
Authorized Shares: 2,000,000,000 a/o Apr 22, 2015
Par Value: 0.001
$FONU extra dd links
Company name: FONU2 Inc.
Company website: http://www.fonu2.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/FONU/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/FONU/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=FONU+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=FONU+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=FONU+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/news - http://finance.yahoo.com/q/h?s=FONU+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/FONU/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/FONU/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/FONU/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/FONU/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=FONU+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/FONU
DTCC (dtcc.com): http://search2.dtcc.com/?q=FONU2+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=FONU2+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=FONU2+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.fonu2.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.fonu2.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.fonu2.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/FONU/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/FONU
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/FONU/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/FONU/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/FONU/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001168325&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/FONU/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/FONU/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=FONU&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=FONU
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=FONU+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=FONU+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=FONU
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=FONU
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=FONU+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/FONU/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=FONU+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/FONU.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=FONU
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/FONU/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/FONU/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/FONU/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/FONU
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/FONU
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/FONU:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=FONU
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=FONU
$FONU ~ FONU2 Inc. due diligence report
$FONU recent news/filings
## source: finance.yahoo.com
Fri, 08 Jan 2016 22:05:51 GMT ~ FONU2 INC. Files SEC form 8-K, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obli
read full: http://biz.yahoo.com/e/160108/fonu8-k.html
*********************************************************
Fri, 18 Dec 2015 21:20:27 GMT ~ FONU2 INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
read full: http://biz.yahoo.com/e/151218/fonu8-k.html
*********************************************************
Fri, 11 Dec 2015 21:03:47 GMT ~ FONU2 INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
read full: http://biz.yahoo.com/e/151211/fonu8-k.html
*********************************************************
Tue, 08 Dec 2015 18:15:38 GMT ~ FONU2 INC. Financials
read full: http://finance.yahoo.com/q/is?s=fonu
*********************************************************
Fri, 04 Dec 2015 21:59:53 GMT ~ FONU2 INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
read full: http://biz.yahoo.com/e/151204/fonu8-k.html
*********************************************************
$FONU charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$FONU company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/FONU/company-info
Ticker: $FONU
OTC Market Place: OTCQB
CIK code: 0001168325
Company name: FONU2 Inc.
Company website: http://www.fonu2.com
Incorporated In: NV, USA
Business Description: FONU2 is a film production and social commerce company that is developing a precision sales and marketing platform that integrates into the social media networks. The Fonu2 platform offers members list, buy, sell, and trade services locally in any neighborhood and anywhere in the world. Fonu2 is a Georgia, U.S. based film production company. Building on the business models of early Hollywood with a modern twist, we are in the process of designing and constructing a fully integrated film production facility that will enable efficiencies of scale and eliminate traditional waste. The Company is focusing on feature film projects that can be filmed on the Company?s property, or surrounding locations, to minimize costs and maximize efficiencies. Located in bucolic Coastal Georgia, we are building a true public/private partnership that will create permanent jobs.Less >>
$FONU share structure
## source: otcmarkets.com
Market Value: $84,769 a/o Jan 11, 2016
Shares Outstanding: 847,689,235 a/o Dec 11, 2015
Float: 34,650,040 a/o Apr 22, 2015
Authorized Shares: 2,000,000,000 a/o Apr 22, 2015
Par Value: 0.001
$FONU extra dd links
Company name: FONU2 Inc.
Company website: http://www.fonu2.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/FONU/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/FONU/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=FONU+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=FONU+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=FONU+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/news - http://finance.yahoo.com/q/h?s=FONU+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/FONU/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/FONU/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/FONU/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/FONU/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/FONU/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=FONU+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/FONU
DTCC (dtcc.com): http://search2.dtcc.com/?q=FONU2+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=FONU2+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=FONU2+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.fonu2.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.fonu2.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.fonu2.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/FONU/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/FONU
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/FONU/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/FONU/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/FONU/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001168325&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/FONU/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/FONU/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=FONU&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=FONU
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=FONU+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=FONU+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=FONU
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=FONU
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=FONU+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/FONU/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=FONU+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/FONU.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=FONU
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/FONU/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/FONU/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/FONU/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/FONU/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/FONU
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/FONU
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/FONU:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=FONU
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=FONU
$CJTF ~ Gold & Silver Mining of Nevada, Inc. due diligence report
$CJTF recent news/filings
## source: finance.yahoo.com
Tue, 08 Dec 2015 18:18:03 GMT ~ GOLD & SILVER MINING OF NEVADA INC Financials
read full: http://finance.yahoo.com/q/is?s=cjtf
*********************************************************
$CJTF charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CJTF company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CJTF/company-info
Ticker: $CJTF
OTC Market Place: OTC Pink Current
CIK code: 0001255379
Company name: Gold & Silver Mining of Nevada, Inc.
Company website: http://www.goldandsilvermining.com
Incorporated In: NV, USA
Business Description: The company is focused on developing and bringing into production mining properties in Nevada that are ready to come into production in the near future. New properties in Nevada are ready for near term production. Announcements concerning new production from these new properties will be made during the coming year. For more information, please visit the company web site at www.GoldandSilverMining.com or call Investor Relations at 801-679-3945. The first property where the most work has been done in assessment, maintenance and development is at Asset #26 (Reveille) where the company has doubled its land position in preparation for additional trenching and drilling activities. Our geologist describes the Reveille district as near the Oro-Nevada rift and at the nexus of several calderas. The mineralization here is similar to other metal deposits found along this regional lineament that are in production such as Round Mountain and Manhattan. These are multi-million ounce, gold and silver deposits. Condor Consultings August 2011 Magnetic Report of the Reveille mining district where the companys claims are located in the middle of the study determined that sulfide mineralization is present from near surface to a depth of approximately 1500 feet. The depth to carbonate host rocks is much less along the western corridor where the company is conducting drilling and trenching activities. In recently concluded early drilling our geologist reports a thick sequence of limestone and dolomite where silver and gold were mined from carbonate replacement deposits at their contacts. Gold and Silver were encountered in all of the drill holes which were completed. This drilling represents the deepest drilling to date in this district with the deepest hole being 600 feet. All of the companys objectives were met with this first drilling program and this set in motion the trenching plan to pinpoint the locations for the next round of drilling to finalize the open pit location and submit the paperwork for the operation permit to begin mining and processing in 2014-15. A future area of focus for the company is at Goldfield Basin where the company has conducted sampling and assay analysis work and and made gold from the samples gathered. The company also has $27 million worth of stockpiled ore near its Reveille and Eureka properties which are to be processed and expect to generate about $6 million net over the next couple years. . Safe Harbor Statement under the Private Securities Litigation ReformAct of 1995This company information may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.Less >>
$CJTF share structure
## source: otcmarkets.com
Market Value: $277,523 a/o Jan 08, 2016
Shares Outstanding: 1,387,613,791 a/o Sep 30, 2015
Float: 387,377,507 a/o Nov 10, 2015
Authorized Shares: 2,000,000,000 a/o Nov 10, 2015
Par Value: 0.001
$CJTF extra dd links
Company name: Gold & Silver Mining of Nevada, Inc.
Company website: http://www.goldandsilvermining.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CJTF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CJTF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CJTF+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/news - http://finance.yahoo.com/q/h?s=CJTF+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CJTF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CJTF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CJTF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Gold+%26+Silver+Mining+of+Nevada%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Gold+%26+Silver+Mining+of+Nevada%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Gold+%26+Silver+Mining+of+Nevada%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.goldandsilvermining.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.goldandsilvermining.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.goldandsilvermining.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CJTF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001255379&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CJTF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CJTF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CJTF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CJTF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CJTF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CJTF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CJTF+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CJTF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CJTF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CJTF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CJTF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CJTF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CJTF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CJTF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CJTF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CJTF
$CJTF ~ Gold & Silver Mining of Nevada, Inc. due diligence report
$CJTF recent news/filings
## source: finance.yahoo.com
Tue, 08 Dec 2015 18:18:03 GMT ~ GOLD & SILVER MINING OF NEVADA INC Financials
read full: http://finance.yahoo.com/q/is?s=cjtf
*********************************************************
$CJTF charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CJTF company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CJTF/company-info
Ticker: $CJTF
OTC Market Place: OTC Pink Current
CIK code: 0001255379
Company name: Gold & Silver Mining of Nevada, Inc.
Company website: http://www.goldandsilvermining.com
Incorporated In: NV, USA
Business Description: The company is focused on developing and bringing into production mining properties in Nevada that are ready to come into production in the near future. New properties in Nevada are ready for near term production. Announcements concerning new production from these new properties will be made during the coming year. For more information, please visit the company web site at www.GoldandSilverMining.com or call Investor Relations at 801-679-3945. The first property where the most work has been done in assessment, maintenance and development is at Asset #26 (Reveille) where the company has doubled its land position in preparation for additional trenching and drilling activities. Our geologist describes the Reveille district as near the Oro-Nevada rift and at the nexus of several calderas. The mineralization here is similar to other metal deposits found along this regional lineament that are in production such as Round Mountain and Manhattan. These are multi-million ounce, gold and silver deposits. Condor Consultings August 2011 Magnetic Report of the Reveille mining district where the companys claims are located in the middle of the study determined that sulfide mineralization is present from near surface to a depth of approximately 1500 feet. The depth to carbonate host rocks is much less along the western corridor where the company is conducting drilling and trenching activities. In recently concluded early drilling our geologist reports a thick sequence of limestone and dolomite where silver and gold were mined from carbonate replacement deposits at their contacts. Gold and Silver were encountered in all of the drill holes which were completed. This drilling represents the deepest drilling to date in this district with the deepest hole being 600 feet. All of the companys objectives were met with this first drilling program and this set in motion the trenching plan to pinpoint the locations for the next round of drilling to finalize the open pit location and submit the paperwork for the operation permit to begin mining and processing in 2014-15. A future area of focus for the company is at Goldfield Basin where the company has conducted sampling and assay analysis work and and made gold from the samples gathered. The company also has $27 million worth of stockpiled ore near its Reveille and Eureka properties which are to be processed and expect to generate about $6 million net over the next couple years. . Safe Harbor Statement under the Private Securities Litigation ReformAct of 1995This company information may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.Less >>
$CJTF share structure
## source: otcmarkets.com
Market Value: $277,523 a/o Jan 08, 2016
Shares Outstanding: 1,387,613,791 a/o Sep 30, 2015
Float: 387,377,507 a/o Nov 10, 2015
Authorized Shares: 2,000,000,000 a/o Nov 10, 2015
Par Value: 0.001
$CJTF extra dd links
Company name: Gold & Silver Mining of Nevada, Inc.
Company website: http://www.goldandsilvermining.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CJTF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CJTF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CJTF+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/news - http://finance.yahoo.com/q/h?s=CJTF+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CJTF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CJTF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CJTF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Gold+%26+Silver+Mining+of+Nevada%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Gold+%26+Silver+Mining+of+Nevada%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Gold+%26+Silver+Mining+of+Nevada%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.goldandsilvermining.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.goldandsilvermining.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.goldandsilvermining.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CJTF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001255379&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CJTF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CJTF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CJTF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CJTF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CJTF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CJTF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CJTF+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CJTF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CJTF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CJTF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CJTF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CJTF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CJTF/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CJTF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CJTF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CJTF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CJTF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CJTF
$BSSP ~ Bassline Productions, Inc. due diligence report
$BSSP recent news/filings
## source: finance.yahoo.com
Thu, 14 Jan 2016 22:25:44 GMT ~ REVE TECHNOLOGIES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or
read full: http://biz.yahoo.com/e/160114/bssp8-k.html
*********************************************************
Tue, 22 Dec 2015 20:50:00 GMT ~ Reve Technologies, Inc. Announces 24 Mo. Capital Purchase Plan
[Accesswire] - To Implement the Capital Purchase Agreement f/k/a CPA; Blueprint for 2016 and 2017 SCOTTSDALE, AZ / ACCESSWIRE / December 22, 2015 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" or "Reve") ...
read full: http://finance.yahoo.com/news/reve-technologies-inc-announces-24-205000179.html
*********************************************************
Tue, 08 Dec 2015 18:18:02 GMT ~ REVE TECHNOLOGIES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=bssp
*********************************************************
Thu, 03 Dec 2015 18:59:00 GMT ~ Reve Technologies, Inc. Appoints William Bozsnyak as a Strategic Advisor to the Board December 3, 2015
[Accesswire] - To Assist Implementation for the Reve Capital Purchase Division SCOTTSDALE, AZ / ACCESSWIRE / December 3, 2015 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" or "Reve") is pleased ...
read full: http://finance.yahoo.com/news/reve-technologies-inc-appoints-william-185900417.html
*********************************************************
Tue, 01 Dec 2015 18:20:00 GMT ~ Reve Announces Initiating Set Up For A New Capital Purchase Division to Launch Q1 2016
[Accesswire] - To Provide Short Term Capital Purchase Assistance across the Diversified Financial Market Sectors SCOTTSDALE, AZ / ACCESSWIRE / December 1, 2015 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" ...
read full: http://finance.yahoo.com/news/reve-announces-initiating-set-capital-182000628.html
*********************************************************
$BSSP charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$BSSP company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BSSP/company-info
Ticker: $BSSP
OTC Market Place: OTC Pink Current
CIK code: 0001495028
Company name: Bassline Productions, Inc.
Company website: http://www.ReveTech.com
Incorporated In: NV, USA
Business Description: Reve Technologies, Inc., f/k/a Bassline Productions, Inc., (OTC BB: BSSP) is a technology company focused on investing in, developing and marketing emerging hardware, mobile and web applications.
$BSSP share structure
## source: otcmarkets.com
Market Value: $37,189 a/o Jan 22, 2016
Shares Outstanding: 371,887,192 a/o Nov 20, 2015
Float: 15,000,000 a/o Sep 26, 2014
Authorized Shares: 100,000,000 a/o Sep 26, 2014
Par Value: 0.001
$BSSP extra dd links
Company name: Bassline Productions, Inc.
Company website: http://www.ReveTech.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BSSP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BSSP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BSSP+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/news - http://finance.yahoo.com/q/h?s=BSSP+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BSSP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BSSP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BSSP
DTCC (dtcc.com): http://search2.dtcc.com/?q=Bassline+Productions%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Bassline+Productions%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Bassline+Productions%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ReveTech.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ReveTech.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ReveTech.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BSSP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001495028&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BSSP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BSSP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BSSP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BSSP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BSSP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BSSP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BSSP+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BSSP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BSSP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BSSP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BSSP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BSSP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BSSP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BSSP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BSSP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BSSP
$BSSP ~ Bassline Productions, Inc. due diligence report
$BSSP recent news/filings
## source: finance.yahoo.com
Thu, 14 Jan 2016 22:25:44 GMT ~ REVE TECHNOLOGIES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or
read full: http://biz.yahoo.com/e/160114/bssp8-k.html
*********************************************************
Tue, 22 Dec 2015 20:50:00 GMT ~ Reve Technologies, Inc. Announces 24 Mo. Capital Purchase Plan
[Accesswire] - To Implement the Capital Purchase Agreement f/k/a CPA; Blueprint for 2016 and 2017 SCOTTSDALE, AZ / ACCESSWIRE / December 22, 2015 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" or "Reve") ...
read full: http://finance.yahoo.com/news/reve-technologies-inc-announces-24-205000179.html
*********************************************************
Tue, 08 Dec 2015 18:18:02 GMT ~ REVE TECHNOLOGIES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=bssp
*********************************************************
Thu, 03 Dec 2015 18:59:00 GMT ~ Reve Technologies, Inc. Appoints William Bozsnyak as a Strategic Advisor to the Board December 3, 2015
[Accesswire] - To Assist Implementation for the Reve Capital Purchase Division SCOTTSDALE, AZ / ACCESSWIRE / December 3, 2015 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" or "Reve") is pleased ...
read full: http://finance.yahoo.com/news/reve-technologies-inc-appoints-william-185900417.html
*********************************************************
Tue, 01 Dec 2015 18:20:00 GMT ~ Reve Announces Initiating Set Up For A New Capital Purchase Division to Launch Q1 2016
[Accesswire] - To Provide Short Term Capital Purchase Assistance across the Diversified Financial Market Sectors SCOTTSDALE, AZ / ACCESSWIRE / December 1, 2015 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" ...
read full: http://finance.yahoo.com/news/reve-announces-initiating-set-capital-182000628.html
*********************************************************
$BSSP charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$BSSP company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BSSP/company-info
Ticker: $BSSP
OTC Market Place: OTC Pink Current
CIK code: 0001495028
Company name: Bassline Productions, Inc.
Company website: http://www.ReveTech.com
Incorporated In: NV, USA
Business Description: Reve Technologies, Inc., f/k/a Bassline Productions, Inc., (OTC BB: BSSP) is a technology company focused on investing in, developing and marketing emerging hardware, mobile and web applications.
$BSSP share structure
## source: otcmarkets.com
Market Value: $37,189 a/o Jan 22, 2016
Shares Outstanding: 371,887,192 a/o Nov 20, 2015
Float: 15,000,000 a/o Sep 26, 2014
Authorized Shares: 100,000,000 a/o Sep 26, 2014
Par Value: 0.001
$BSSP extra dd links
Company name: Bassline Productions, Inc.
Company website: http://www.ReveTech.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BSSP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BSSP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BSSP+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/news - http://finance.yahoo.com/q/h?s=BSSP+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BSSP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BSSP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BSSP
DTCC (dtcc.com): http://search2.dtcc.com/?q=Bassline+Productions%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Bassline+Productions%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Bassline+Productions%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ReveTech.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ReveTech.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ReveTech.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BSSP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001495028&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BSSP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BSSP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BSSP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BSSP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BSSP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BSSP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BSSP+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BSSP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BSSP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BSSP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BSSP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BSSP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BSSP/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BSSP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BSSP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BSSP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BSSP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BSSP
$DOLV ~ Dolat Ventures, Inc. due diligence report
$DOLV recent news/filings
## source: finance.yahoo.com
Tue, 06 Oct 2015 11:24:00 GMT ~ Small Cap Stocks Remain In Spotlight As Earnings Season Begins
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / October 6, 2015 / The beginning of October marks the commencement of earnings season for many companies looking to report growth following a mixed third quarter. The Fed's ...
read full: http://finance.yahoo.com/news/small-cap-stocks-remain-spotlight-112400708.html
*********************************************************
Thu, 23 Jul 2015 17:04:07 GMT ~ DOLAT VENTURES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=dolv
*********************************************************
Fri, 12 Dec 2014 21:57:00 GMT ~ Dolat Ventures Inc. To Reduce Outstanding Stock
[Business Wire] - Dolat Ventures Inc. announced today that its officers and directors are returning all 8,161,244 common shares held by its officers and director in exchange for preferred stock.
read full: http://finance.yahoo.com/news/dolat-ventures-inc-reduce-outstanding-215700768.html
*********************************************************
Tue, 09 Dec 2014 14:00:00 GMT ~ Dolat Ventures Inc. Moves Forward With Private Investment into Diamond Mine Assets
[Business Wire] - Dolat Ventures Inc. announced today that it has completed a corporate restructuring and that Millenium Mining LLC its wholly owned subsidiary has signed a joint venture partnership with a private investor to restart diamond mining at its mining location near Bo, Sierra Leone.
read full: http://finance.yahoo.com/news/dolat-ventures-inc-moves-forward-140000398.html
*********************************************************
Mon, 01 Dec 2014 14:21:00 GMT ~ Dolat Ventures Inc. Completes Corporate Restructuring
[Business Wire] - Dolat Ventures Inc. announced today that it has completed a corporate restructuring and that Millenium Mining LLC its wholly owned subsidiary has signed a joint venture partnership with a private investor to restart diamond mining at its mining location near Bo, Sierra Leone.
read full: http://finance.yahoo.com/news/dolat-ventures-inc-completes-corporate-142100931.html
*********************************************************
$DOLV charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$DOLV company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/DOLV/company-info
Ticker: $DOLV
OTC Market Place: OTC Pink Current
CIK code: 0001436568
Company name: Dolat Ventures, Inc.
Company website: http://www.dolatventures.com
Incorporated In: WY, USA
Business Description: Dolat Ventures, Dove Diamonds & Mining was formed to prospect for, mine, extract, cut, polish, buy, sell, export, handle and otherwise deal in diamonds and other precious stones, and metals in Sierra Leone.Dove Diamonds & Mining has chosen to explore and mine the Baimbawai Pool in the Sewa River in Sierra Leone based on its past output as its produced high quality diamonds and gems for the long term. Sierra Leone has been a major diamond producer for 70 years and Dove Diamonds & Mining intends to be one of the leading full scale industrial Diamond Mining firms in Sierra Leone. Alluvial diamonds were first discovered in Bo District in 1930 and Dove Diamonds & Mining is already producing quality diamonds and gems for international markets.With excellent government relations, and local partners and a long history working within Sierra Leone, the principals of Dove Diamonds & Mining have an established track record and the right relationships in Sierra Leone. Dove Diamonds & Mining shall be responsible for all required machinery, mining equipment and will work in compliance with the Mines and Minerals Act of Sierra LeoneLess >>
$DOLV share structure
## source: otcmarkets.com
Market Value: $142,172 a/o Oct 29, 2015
Shares Outstanding: 83,630,586 a/o Oct 13, 2015
Float: 21,032,785 a/o Oct 13, 2015
Authorized Shares: 500,000,000 a/o Oct 13, 2015
Par Value: 0.001
$DOLV extra dd links
Company name: Dolat Ventures, Inc.
Company website: http://www.dolatventures.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DOLV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DOLV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DOLV+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/news - http://finance.yahoo.com/q/h?s=DOLV+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DOLV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DOLV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DOLV
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dolat+Ventures%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dolat+Ventures%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dolat+Ventures%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.dolatventures.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.dolatventures.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.dolatventures.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DOLV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001436568&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DOLV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DOLV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DOLV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DOLV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DOLV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DOLV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DOLV+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DOLV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DOLV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DOLV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DOLV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DOLV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DOLV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DOLV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DOLV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DOLV
$DOLV ~ Dolat Ventures, Inc. due diligence report
$DOLV recent news/filings
## source: finance.yahoo.com
Tue, 06 Oct 2015 11:24:00 GMT ~ Small Cap Stocks Remain In Spotlight As Earnings Season Begins
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / October 6, 2015 / The beginning of October marks the commencement of earnings season for many companies looking to report growth following a mixed third quarter. The Fed's ...
read full: http://finance.yahoo.com/news/small-cap-stocks-remain-spotlight-112400708.html
*********************************************************
Thu, 23 Jul 2015 17:04:07 GMT ~ DOLAT VENTURES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=dolv
*********************************************************
Fri, 12 Dec 2014 21:57:00 GMT ~ Dolat Ventures Inc. To Reduce Outstanding Stock
[Business Wire] - Dolat Ventures Inc. announced today that its officers and directors are returning all 8,161,244 common shares held by its officers and director in exchange for preferred stock.
read full: http://finance.yahoo.com/news/dolat-ventures-inc-reduce-outstanding-215700768.html
*********************************************************
Tue, 09 Dec 2014 14:00:00 GMT ~ Dolat Ventures Inc. Moves Forward With Private Investment into Diamond Mine Assets
[Business Wire] - Dolat Ventures Inc. announced today that it has completed a corporate restructuring and that Millenium Mining LLC its wholly owned subsidiary has signed a joint venture partnership with a private investor to restart diamond mining at its mining location near Bo, Sierra Leone.
read full: http://finance.yahoo.com/news/dolat-ventures-inc-moves-forward-140000398.html
*********************************************************
Mon, 01 Dec 2014 14:21:00 GMT ~ Dolat Ventures Inc. Completes Corporate Restructuring
[Business Wire] - Dolat Ventures Inc. announced today that it has completed a corporate restructuring and that Millenium Mining LLC its wholly owned subsidiary has signed a joint venture partnership with a private investor to restart diamond mining at its mining location near Bo, Sierra Leone.
read full: http://finance.yahoo.com/news/dolat-ventures-inc-completes-corporate-142100931.html
*********************************************************
$DOLV charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$DOLV company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/DOLV/company-info
Ticker: $DOLV
OTC Market Place: OTC Pink Current
CIK code: 0001436568
Company name: Dolat Ventures, Inc.
Company website: http://www.dolatventures.com
Incorporated In: WY, USA
Business Description: Dolat Ventures, Dove Diamonds & Mining was formed to prospect for, mine, extract, cut, polish, buy, sell, export, handle and otherwise deal in diamonds and other precious stones, and metals in Sierra Leone.Dove Diamonds & Mining has chosen to explore and mine the Baimbawai Pool in the Sewa River in Sierra Leone based on its past output as its produced high quality diamonds and gems for the long term. Sierra Leone has been a major diamond producer for 70 years and Dove Diamonds & Mining intends to be one of the leading full scale industrial Diamond Mining firms in Sierra Leone. Alluvial diamonds were first discovered in Bo District in 1930 and Dove Diamonds & Mining is already producing quality diamonds and gems for international markets.With excellent government relations, and local partners and a long history working within Sierra Leone, the principals of Dove Diamonds & Mining have an established track record and the right relationships in Sierra Leone. Dove Diamonds & Mining shall be responsible for all required machinery, mining equipment and will work in compliance with the Mines and Minerals Act of Sierra LeoneLess >>
$DOLV share structure
## source: otcmarkets.com
Market Value: $142,172 a/o Oct 29, 2015
Shares Outstanding: 83,630,586 a/o Oct 13, 2015
Float: 21,032,785 a/o Oct 13, 2015
Authorized Shares: 500,000,000 a/o Oct 13, 2015
Par Value: 0.001
$DOLV extra dd links
Company name: Dolat Ventures, Inc.
Company website: http://www.dolatventures.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DOLV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DOLV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DOLV+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/news - http://finance.yahoo.com/q/h?s=DOLV+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DOLV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DOLV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DOLV
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dolat+Ventures%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dolat+Ventures%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dolat+Ventures%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.dolatventures.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.dolatventures.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.dolatventures.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DOLV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001436568&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DOLV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DOLV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DOLV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DOLV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DOLV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DOLV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DOLV+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DOLV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DOLV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DOLV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DOLV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DOLV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DOLV/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DOLV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DOLV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DOLV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DOLV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DOLV
$BMSN ~ Bio-Matrix Scientific Group, Inc. due diligence report
$BMSN recent news/filings
## source: finance.yahoo.com
Fri, 08 Jan 2016 11:36:44 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 10-K, Annual Report
read full: http://biz.yahoo.com/e/160108/bmsn10-k.html
*********************************************************
Thu, 17 Dec 2015 11:05:08 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
read full: http://biz.yahoo.com/e/151217/bmsn8-k.html
*********************************************************
Tue, 15 Dec 2015 11:06:13 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/151215/bmsn8-k.html
*********************************************************
Tue, 08 Dec 2015 18:14:33 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Financials
read full: http://finance.yahoo.com/q/is?s=bmsn
*********************************************************
Tue, 24 Nov 2015 21:39:49 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/151124/bmsn8-k.html
*********************************************************
$BMSN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$BMSN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BMSN/company-info
Ticker: $BMSN
OTC Market Place: OTC Pink Current
CIK code: 0001079282
Company name: Bio-Matrix Scientific Group, Inc.
Company website: http://www.bmsn.us
Incorporated In: DE, USA
Business Description: Bio-Matrix Scientific Group Inc. is a biotechnology research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.Bio-Matrix is pursuing relationships with hospitals, medical institutes, research firms and biotechnology companies to assist in stem cell research, cell culturing and Regenerative Medicine therapies. Bio-Matrix? facilities are available for processing, culturing and storage of specimens. Also, under certain situations, the Company has laboratories available to organizations conducting research.Areas of Interest:Cord and Peripheral Blood BankingStem Cell Research Alliances / PartneringCell Culturing ProjectsDiabetes Related ResearchBio-Matrix Scientific Group is poised to work with both domestic and international entitiesLess >>
$BMSN share structure
## source: otcmarkets.com
Market Value: $1,269,879 a/o Jan 08, 2016
Shares Outstanding: 4,232,931,245 a/o Jun 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001
$BMSN extra dd links
Company name: Bio-Matrix Scientific Group, Inc.
Company website: http://www.bmsn.us
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BMSN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BMSN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BMSN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/news - http://finance.yahoo.com/q/h?s=BMSN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BMSN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BMSN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BMSN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Bio-Matrix+Scientific+Group%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Bio-Matrix+Scientific+Group%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Bio-Matrix+Scientific+Group%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.bmsn.us
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.bmsn.us#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.bmsn.us
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BMSN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001079282&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BMSN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BMSN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BMSN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BMSN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BMSN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BMSN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BMSN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BMSN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BMSN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BMSN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BMSN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BMSN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BMSN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BMSN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BMSN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BMSN
$BMSN ~ Bio-Matrix Scientific Group, Inc. due diligence report
$BMSN recent news/filings
## source: finance.yahoo.com
Fri, 08 Jan 2016 11:36:44 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 10-K, Annual Report
read full: http://biz.yahoo.com/e/160108/bmsn10-k.html
*********************************************************
Thu, 17 Dec 2015 11:05:08 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
read full: http://biz.yahoo.com/e/151217/bmsn8-k.html
*********************************************************
Tue, 15 Dec 2015 11:06:13 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/151215/bmsn8-k.html
*********************************************************
Tue, 08 Dec 2015 18:14:33 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Financials
read full: http://finance.yahoo.com/q/is?s=bmsn
*********************************************************
Tue, 24 Nov 2015 21:39:49 GMT ~ BIO-MATRIX SCIENTIFIC GROUP, INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/151124/bmsn8-k.html
*********************************************************
$BMSN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$BMSN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BMSN/company-info
Ticker: $BMSN
OTC Market Place: OTC Pink Current
CIK code: 0001079282
Company name: Bio-Matrix Scientific Group, Inc.
Company website: http://www.bmsn.us
Incorporated In: DE, USA
Business Description: Bio-Matrix Scientific Group Inc. is a biotechnology research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.Bio-Matrix is pursuing relationships with hospitals, medical institutes, research firms and biotechnology companies to assist in stem cell research, cell culturing and Regenerative Medicine therapies. Bio-Matrix? facilities are available for processing, culturing and storage of specimens. Also, under certain situations, the Company has laboratories available to organizations conducting research.Areas of Interest:Cord and Peripheral Blood BankingStem Cell Research Alliances / PartneringCell Culturing ProjectsDiabetes Related ResearchBio-Matrix Scientific Group is poised to work with both domestic and international entitiesLess >>
$BMSN share structure
## source: otcmarkets.com
Market Value: $1,269,879 a/o Jan 08, 2016
Shares Outstanding: 4,232,931,245 a/o Jun 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001
$BMSN extra dd links
Company name: Bio-Matrix Scientific Group, Inc.
Company website: http://www.bmsn.us
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BMSN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BMSN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BMSN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/news - http://finance.yahoo.com/q/h?s=BMSN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BMSN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BMSN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BMSN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Bio-Matrix+Scientific+Group%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Bio-Matrix+Scientific+Group%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Bio-Matrix+Scientific+Group%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.bmsn.us
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.bmsn.us#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.bmsn.us
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BMSN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001079282&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BMSN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BMSN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BMSN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BMSN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BMSN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BMSN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BMSN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BMSN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BMSN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BMSN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BMSN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BMSN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BMSN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BMSN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BMSN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BMSN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BMSN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BMSN
$PMCB ~ PharmaCyte Biotech, Inc. DD
$PMCB PharmaCyte Biotech - Diabetes Treatment Program
$PMCB ~ PharmaCyte Biotech, Inc. DD
$PMCB PharmaCyte Biotech - Diabetes Treatment Program
$PMCB PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial
SILVER SPRING, Md., Jan. 04, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as this is the year that we will get into the clinic with our pancreatic cancer treatment. Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”
Waggoner highlighted the 2016 milestones that PharmaCyte’s shareholders and investment community can look forward to this year:
PharmaCyte’s CEO will attend the 2016 JP Morgan Healthcare conference in San Francisco to meet with pharmaceutical companies and potential institutional investors.
The manufacturing facility in Bangkok, Thailand, where the live cells that convert the cancer prodrug ifosfamide into its cancer-killing form will be encapsulated, will receive a factory license from the Thai government enabling production of the encapsulated cells for PharmaCyte to use in its clinical trials.
The Austrianova manufacturing facility will become fully compliant with current Good Manufacturing Practices (cGMP) standards.
An Investigational New Drug Application (IND) will be filed with the FDA following a pre-IND meeting with the FDA.
Appropriate arrangements will be made with cancer centers in the United States to begin PharmaCyte’s pancreatic cancer trial that will address the critical unmet medical need that exists when a patient’s non-metastatic, pancreatic cancer no longer benefits from receiving the “gold standard” treatment – the combination of gemcitabine and Abraxane®.
PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.
After the pancreatic cancer clinical trial has been in process for approximately six months, there will be an evaluation of PharmaCyte’s pancreatic cancer treatment on the patients enrolled in the trial with the interim results being reported to the public.
Additional preclinical studies to determine if PharmaCyte’s pancreatic cancer treatment can slow down the production and accumulation of malignant ascites fluid will take place in 2016. If successful, plans to conduct a clinical trial in ascites will be undertaken by PharmaCyte with the goal of having TD2 begin the clinical trial by year end or early 2017.
Numerous preclinical studies will be conducted concurrently and in parallel by members of PharmaCyte’s international Diabetes Consortium to condense the time it will take for PharmaCyte to enter into a clinical trial that will test the ability of the Melligen insulin-producing cells encapsulated using the Cell-in-a-Box® technology to treat Type 1 diabetes and insulin-dependent Type 2 diabetes, with the goal of reaching the clinic in 2017.
PharmaCyte will fill its open Board of Directors positions as appropriate.
PharmaCyte will conduct periodic shareholder calls, rather than communicating through shareholder updates, with the CEO responding to questions during the calls.
PharmaCyte will hold an annual shareholder meeting.
PharmaCyte’s Chief Operating Officer, Dr. Gerald W. Crabtree stated, “2016 promises to be both busy and productive for the Company and those associated with it. Of course the major highlight will be the start of our clinical trial in pancreatic cancer.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial
SILVER SPRING, Md., Jan. 04, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as this is the year that we will get into the clinic with our pancreatic cancer treatment. Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”
Waggoner highlighted the 2016 milestones that PharmaCyte’s shareholders and investment community can look forward to this year:
PharmaCyte’s CEO will attend the 2016 JP Morgan Healthcare conference in San Francisco to meet with pharmaceutical companies and potential institutional investors.
The manufacturing facility in Bangkok, Thailand, where the live cells that convert the cancer prodrug ifosfamide into its cancer-killing form will be encapsulated, will receive a factory license from the Thai government enabling production of the encapsulated cells for PharmaCyte to use in its clinical trials.
The Austrianova manufacturing facility will become fully compliant with current Good Manufacturing Practices (cGMP) standards.
An Investigational New Drug Application (IND) will be filed with the FDA following a pre-IND meeting with the FDA.
Appropriate arrangements will be made with cancer centers in the United States to begin PharmaCyte’s pancreatic cancer trial that will address the critical unmet medical need that exists when a patient’s non-metastatic, pancreatic cancer no longer benefits from receiving the “gold standard” treatment – the combination of gemcitabine and Abraxane®.
PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.
After the pancreatic cancer clinical trial has been in process for approximately six months, there will be an evaluation of PharmaCyte’s pancreatic cancer treatment on the patients enrolled in the trial with the interim results being reported to the public.
Additional preclinical studies to determine if PharmaCyte’s pancreatic cancer treatment can slow down the production and accumulation of malignant ascites fluid will take place in 2016. If successful, plans to conduct a clinical trial in ascites will be undertaken by PharmaCyte with the goal of having TD2 begin the clinical trial by year end or early 2017.
Numerous preclinical studies will be conducted concurrently and in parallel by members of PharmaCyte’s international Diabetes Consortium to condense the time it will take for PharmaCyte to enter into a clinical trial that will test the ability of the Melligen insulin-producing cells encapsulated using the Cell-in-a-Box® technology to treat Type 1 diabetes and insulin-dependent Type 2 diabetes, with the goal of reaching the clinic in 2017.
PharmaCyte will fill its open Board of Directors positions as appropriate.
PharmaCyte will conduct periodic shareholder calls, rather than communicating through shareholder updates, with the CEO responding to questions during the calls.
PharmaCyte will hold an annual shareholder meeting.
PharmaCyte’s Chief Operating Officer, Dr. Gerald W. Crabtree stated, “2016 promises to be both busy and productive for the Company and those associated with it. Of course the major highlight will be the start of our clinical trial in pancreatic cancer.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the following developments since the Company’s last shareholder update:
PharmaCyte announced a complete redesign of its clinical trial in advanced pancreatic cancer. After consulting with world-renowned experts in the filed of pancreatic cancer; including, Dr. Mathias Löhr, Dr. Manuel Hidalgo, and experts at Translational Drug Development (TD2), PharmaCyte’s Phase 2b clinical trial was completely redesigned in an attempt to satisfy a critical unmet medical need that exists for patients with inoperable, but not metastatic, pancreatic cancer whose tumors no longer respond after 4 to 6 months of treatment with the current “gold standard” for the disease, the combination of Abraxane® plus gemcitabine. In most cases, therapy consisting of another chemotherapy agent plus radiation is given to such patients. However, the beneficial effects of these treatments are marginal at best.
The clinical trial will now be conducted in the United States by TD2 with study sites in both Europe and Australia.
Eligible patients will be randomly placed into two groups. Group 1 will receive PharmaCyte’s pancreatic cancer treatment of Cell-in-a-Box® plus low doses of ifosfamide. Group 2 will receive treatment with the combination of capecitabine + radiation.
The primary endpoints for the trial will be: (i) progression-free survival (PSF); and (ii) the side effects that occur in the patients. PSF is the time that elapses from the first day of treatment until the disease gets worse. The trial design also includes several secondary endpoints; the most important of which are: (i) the onset of pain and the patient’s need for pain medications; (ii) whether the inoperable tumors become operable as a result of the treatment; (iii) the change in tumor size; and (iv) the patients’ overall quality of life during the treatment.
PharmaCyte will now include in this trial the evaluation of its pancreatic cancer treatment on the treatment of pain, a severe consequence of pancreatic cancer. A separate clinical trial on pancreatic cancer pain is no longer necessary.
Regarding PharmaCyte’s work on ascites fluid production and accumulation, a series of additional preclinical studies has been initiated and are being continued by TD2. The initial studies using an ovarian tumor model in mice indicated that PharmaCyte’s pancreatic cancer treatment might have value in treating the malignant ascites fluid condition. These preclinical studies are now being continued with other abdominal tumor models, beginning with colon cancer, in an effort to better define the conditions under which PharmaCyte’s pancreatic cancer treatment can modulate the production or accumulation of malignant ascites fluid.
In late 2015, PharmaCyte obtained the Orphan Drug designation (ODD) for its pancreatic cancer treatment from the European Medicines Agency (EMA). With this designation, PharmaCyte now has ODD in Europe and the United States, which was obtained in late 2014 when the FDA granted the ODD to PharmaCyte. Obtaining the ODD allows for 10 years of marketing exclusivity in the European Union and 7 years of marketing exclusivity in the United States upon approval by the EMA and the FDA of PharmaCyte’s pancreatic cancer treatment.
PharmaCyte appointed Dr. Manuel Hidalgo as a member of its Scientific Advisory Board and as a consultant. For several years, Dr. Hidalgo worked closely with pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2. Recently, Dr. Hidalgo was appointed Head of Hematology and Oncology at the Beth Israel Deaconess Hospital in Boston, an institution that is affiliated with the renowned Dana-Farber Cancer Institute in Boston.
PharmaCyte contracted with Imaging Endpoints, one of America’s leading Contract Research Organizations for radiologic imaging, to perform the radiologic imaging that will be the cornerstone of many of the measurements conducted during the pancreatic cancer clinical trial.
Prior to the initiation of a clinical trial, an Investigational New Drug Application (IND) must be filed and reviewed by the FDA. A major part of the IND is a section termed “Chemistry, Manufacturing and Controls” or “CMC.” Within the CMC section, a pivotal portion describes the characteristics of the drug or treatment production facility and supplies supporting documentation to ensure that the facility meets cGMP standards. PharmaCyte retained CMC experts Chamow and Associates (Chamow) to assist in evaluating the facility in Bangkok, Thailand, that will produce and supply the Cell-in-a-Box® technology for PharmaCyte’s clinical trial, and in preparing the relevant portions of the CMC section of the IND for submission to the FDA and other regulatory agencies. PharmaCyte and TD2 are awaiting receipt of Chamow’s audit report to finalize the timeline for commencement of the clinical trial.
In November 2015, the second annual meeting of the international Diabetes Consortium was held in Vienna, Austria. Members of the Consortium presented results of studies done to date and finalized research plans for future studies. A video that discusses PharmaCyte’s diabetes program was filmed at the meeting and can be viewed at www.PharmaCyte.com/diabetes.
A guest at the meeting of the Diabetes Consortium was Prof. Dr. Hans-Peter Hammes, one of Europe’s leading authorities on diabetes and its complications. Dr. Hammes currently serves as Section Head of Endocrinology at the 5th Medical Department, University Medical Center Mannheim at the University of Heidelberg in Germany. Dr. Hammes received the prestigious Camillo Golgi Prize awarded at the 2015 meeting of the European Association for the Study of Diabetes. After attending the Diabetes Consortium meeting and becoming acquainted with the Consortium members, Dr. Hammes agreed to join PharmaCyte’s Scientific Advisory Board and become a member of the Consortium. Dr. Hammes also agreed to serve as a consultant to PharmaCyte.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the following developments since the Company’s last shareholder update:
PharmaCyte announced a complete redesign of its clinical trial in advanced pancreatic cancer. After consulting with world-renowned experts in the filed of pancreatic cancer; including, Dr. Mathias Löhr, Dr. Manuel Hidalgo, and experts at Translational Drug Development (TD2), PharmaCyte’s Phase 2b clinical trial was completely redesigned in an attempt to satisfy a critical unmet medical need that exists for patients with inoperable, but not metastatic, pancreatic cancer whose tumors no longer respond after 4 to 6 months of treatment with the current “gold standard” for the disease, the combination of Abraxane® plus gemcitabine. In most cases, therapy consisting of another chemotherapy agent plus radiation is given to such patients. However, the beneficial effects of these treatments are marginal at best.
The clinical trial will now be conducted in the United States by TD2 with study sites in both Europe and Australia.
Eligible patients will be randomly placed into two groups. Group 1 will receive PharmaCyte’s pancreatic cancer treatment of Cell-in-a-Box® plus low doses of ifosfamide. Group 2 will receive treatment with the combination of capecitabine + radiation.
The primary endpoints for the trial will be: (i) progression-free survival (PSF); and (ii) the side effects that occur in the patients. PSF is the time that elapses from the first day of treatment until the disease gets worse. The trial design also includes several secondary endpoints; the most important of which are: (i) the onset of pain and the patient’s need for pain medications; (ii) whether the inoperable tumors become operable as a result of the treatment; (iii) the change in tumor size; and (iv) the patients’ overall quality of life during the treatment.
PharmaCyte will now include in this trial the evaluation of its pancreatic cancer treatment on the treatment of pain, a severe consequence of pancreatic cancer. A separate clinical trial on pancreatic cancer pain is no longer necessary.
Regarding PharmaCyte’s work on ascites fluid production and accumulation, a series of additional preclinical studies has been initiated and are being continued by TD2. The initial studies using an ovarian tumor model in mice indicated that PharmaCyte’s pancreatic cancer treatment might have value in treating the malignant ascites fluid condition. These preclinical studies are now being continued with other abdominal tumor models, beginning with colon cancer, in an effort to better define the conditions under which PharmaCyte’s pancreatic cancer treatment can modulate the production or accumulation of malignant ascites fluid.
In late 2015, PharmaCyte obtained the Orphan Drug designation (ODD) for its pancreatic cancer treatment from the European Medicines Agency (EMA). With this designation, PharmaCyte now has ODD in Europe and the United States, which was obtained in late 2014 when the FDA granted the ODD to PharmaCyte. Obtaining the ODD allows for 10 years of marketing exclusivity in the European Union and 7 years of marketing exclusivity in the United States upon approval by the EMA and the FDA of PharmaCyte’s pancreatic cancer treatment.
PharmaCyte appointed Dr. Manuel Hidalgo as a member of its Scientific Advisory Board and as a consultant. For several years, Dr. Hidalgo worked closely with pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2. Recently, Dr. Hidalgo was appointed Head of Hematology and Oncology at the Beth Israel Deaconess Hospital in Boston, an institution that is affiliated with the renowned Dana-Farber Cancer Institute in Boston.
PharmaCyte contracted with Imaging Endpoints, one of America’s leading Contract Research Organizations for radiologic imaging, to perform the radiologic imaging that will be the cornerstone of many of the measurements conducted during the pancreatic cancer clinical trial.
Prior to the initiation of a clinical trial, an Investigational New Drug Application (IND) must be filed and reviewed by the FDA. A major part of the IND is a section termed “Chemistry, Manufacturing and Controls” or “CMC.” Within the CMC section, a pivotal portion describes the characteristics of the drug or treatment production facility and supplies supporting documentation to ensure that the facility meets cGMP standards. PharmaCyte retained CMC experts Chamow and Associates (Chamow) to assist in evaluating the facility in Bangkok, Thailand, that will produce and supply the Cell-in-a-Box® technology for PharmaCyte’s clinical trial, and in preparing the relevant portions of the CMC section of the IND for submission to the FDA and other regulatory agencies. PharmaCyte and TD2 are awaiting receipt of Chamow’s audit report to finalize the timeline for commencement of the clinical trial.
In November 2015, the second annual meeting of the international Diabetes Consortium was held in Vienna, Austria. Members of the Consortium presented results of studies done to date and finalized research plans for future studies. A video that discusses PharmaCyte’s diabetes program was filmed at the meeting and can be viewed at www.PharmaCyte.com/diabetes.
A guest at the meeting of the Diabetes Consortium was Prof. Dr. Hans-Peter Hammes, one of Europe’s leading authorities on diabetes and its complications. Dr. Hammes currently serves as Section Head of Endocrinology at the 5th Medical Department, University Medical Center Mannheim at the University of Heidelberg in Germany. Dr. Hammes received the prestigious Camillo Golgi Prize awarded at the 2015 meeting of the European Association for the Study of Diabetes. After attending the Diabetes Consortium meeting and becoming acquainted with the Consortium members, Dr. Hammes agreed to join PharmaCyte’s Scientific Advisory Board and become a member of the Consortium. Dr. Hammes also agreed to serve as a consultant to PharmaCyte.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.
Abdominal Cancers
According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:
Colorectal: 132,000
Liver: 62,000
Pancreatic: 49,000
Ovarian: 22,000
To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.
PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.
PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.
Breast Cancer
PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.
In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.
Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.
The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.
Abdominal Cancers
According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:
Colorectal: 132,000
Liver: 62,000
Pancreatic: 49,000
Ovarian: 22,000
To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.
PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.
PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.
Breast Cancer
PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.
In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.
Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.
The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
$PMCB Pharmacyte Biotech is About to Light the Fuse
Pharmacyte Biotech Inc. (OTCMKTS:PMCB) CEO Ken Waggoner is about to shake hands with a small army of movers and shakers.
Don't be too surprised if things seem a little more lively for Pharmacyte Biotech Inc. (OTCMKTS:PMCB) beginning next week.... trading activity, media coverage, and maybe even a partner or financial backer. The company's CEO Kenneth L. Waggoner will be attending this year's annual J.P. Morgan Healthcare Conference, which always seems to stir the pot, so to speak, for the company's in attendance. PMCB isn't apt to be an exception.
The invitation-only event pulls together institutional investors and biotech companies, and has become a much bigger event than J.P. Morgan ever foresaw when it started hosting the conference more than three decades ago. Now the entire area around the conference also hosts several other ancillary events that ultimate lead to deals, funding, and networking.
This year's conference will take place between January 11th and the 14th in San Francisco, California.
The event could prove to be a real boon for Pharmacyte Biotech, as it's headed into the event well-positioned with a tremendous pipeline and market opportunity.
PharmaCyte Biotech is the developer of a patented technology called Cell-in-a-Box(r) ... a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.
In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream in the upper part of the leg maximizes delivery of the active form of the drug to the cancer-ridden pancreas. Ergo, this approach has proven superior to activation of the drug in the liver.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients. The next stage of the trial will pit ifosfamide against the gemcitabine/Abraxane combination, which is the proverbial gold standard (for now) among pancreatic cancer treatment options.
The real star of the show, however, is the Cell-in-a-Box(r) technology, which makes the activation of ifosfamide possible.
As was noted, inside each encapsulation are thousands of living cells, engineered to take on a very specific role. In the case of pancreatic cancer, PharmaCyte Biotech has enclosed cells that produce the same P450 enzyme the liver would produce to activate ifosfamide. The only difference is the point of activation -- the leg rather than the liver.
Those who've followed the premise of live-cell encapsulation will know it's not been an easy road to navigate. The ideal material for the "shell" of these encapsulations is a cellulose-based material, but most trials of various cellulose materials have failed in the sense that either the body's immune system successfully attacked them (seeing these cells as outside invaders) , or the encapsulations themselves structurally failed.
PharmaCyte Biotech, however, seems to have found the right formula to make the encapsulations.
The combination of two proprietary polymers and a propriety droplet-forming process has allowed the company to achieve what had been fairly elusive for other researchers up until this point. The hardened polymer combination is still cellulose-based, allowing it to let nutrients in and allow the P450 enzyme out. But, the tough shell also prevents the patient's own immune system from attacking and killing the cells living inside the capsules.
Clearly the technology and premise have the potential to be a game-changer in terms of drug delivery, as the Cell-in-a-Box(r) technology can encapsulate a wide variety of cells....and not just cells that help fight cancer. PharmaCyte Biotech is even working on using encapsulate insulin-producing cells as a therapy for diabetes. Even then, the application of the idea has only scratched the surface of its potential.
There's no word yet on if PharmaCyte will be offering an online webcast from any presentations it makes at the conference, but it's very likely the company will be releasing some sort of update or wrap-up report after the event. More important though, it's a chance to get its story out in front of Wall Street's and the biotech industry's most centers of influence, which bodes well for PMCB shares (which have already been on a tear following last week's capitulation).
$PMCB Pharmacyte Biotech is About to Light the Fuse
Pharmacyte Biotech Inc. (OTCMKTS:PMCB) CEO Ken Waggoner is about to shake hands with a small army of movers and shakers.
Don't be too surprised if things seem a little more lively for Pharmacyte Biotech Inc. (OTCMKTS:PMCB) beginning next week.... trading activity, media coverage, and maybe even a partner or financial backer. The company's CEO Kenneth L. Waggoner will be attending this year's annual J.P. Morgan Healthcare Conference, which always seems to stir the pot, so to speak, for the company's in attendance. PMCB isn't apt to be an exception.
The invitation-only event pulls together institutional investors and biotech companies, and has become a much bigger event than J.P. Morgan ever foresaw when it started hosting the conference more than three decades ago. Now the entire area around the conference also hosts several other ancillary events that ultimate lead to deals, funding, and networking.
This year's conference will take place between January 11th and the 14th in San Francisco, California.
The event could prove to be a real boon for Pharmacyte Biotech, as it's headed into the event well-positioned with a tremendous pipeline and market opportunity.
PharmaCyte Biotech is the developer of a patented technology called Cell-in-a-Box(r) ... a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.
In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream in the upper part of the leg maximizes delivery of the active form of the drug to the cancer-ridden pancreas. Ergo, this approach has proven superior to activation of the drug in the liver.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients. The next stage of the trial will pit ifosfamide against the gemcitabine/Abraxane combination, which is the proverbial gold standard (for now) among pancreatic cancer treatment options.
The real star of the show, however, is the Cell-in-a-Box(r) technology, which makes the activation of ifosfamide possible.
As was noted, inside each encapsulation are thousands of living cells, engineered to take on a very specific role. In the case of pancreatic cancer, PharmaCyte Biotech has enclosed cells that produce the same P450 enzyme the liver would produce to activate ifosfamide. The only difference is the point of activation -- the leg rather than the liver.
Those who've followed the premise of live-cell encapsulation will know it's not been an easy road to navigate. The ideal material for the "shell" of these encapsulations is a cellulose-based material, but most trials of various cellulose materials have failed in the sense that either the body's immune system successfully attacked them (seeing these cells as outside invaders) , or the encapsulations themselves structurally failed.
PharmaCyte Biotech, however, seems to have found the right formula to make the encapsulations.
The combination of two proprietary polymers and a propriety droplet-forming process has allowed the company to achieve what had been fairly elusive for other researchers up until this point. The hardened polymer combination is still cellulose-based, allowing it to let nutrients in and allow the P450 enzyme out. But, the tough shell also prevents the patient's own immune system from attacking and killing the cells living inside the capsules.
Clearly the technology and premise have the potential to be a game-changer in terms of drug delivery, as the Cell-in-a-Box(r) technology can encapsulate a wide variety of cells....and not just cells that help fight cancer. PharmaCyte Biotech is even working on using encapsulate insulin-producing cells as a therapy for diabetes. Even then, the application of the idea has only scratched the surface of its potential.
There's no word yet on if PharmaCyte will be offering an online webcast from any presentations it makes at the conference, but it's very likely the company will be releasing some sort of update or wrap-up report after the event. More important though, it's a chance to get its story out in front of Wall Street's and the biotech industry's most centers of influence, which bodes well for PMCB shares (which have already been on a tear following last week's capitulation).
$PMCB If You Like Islet Sciences, You'll Love Pharmacyte Biotech
Islet Sciences Inc. (OTCMKTS:ISLT) shares were all the rage on Monday, but Pharmacyte Biotech Inc. (OTCMKTS:PMCB) remains one of the market's most compelling penny stocks in the diabetes treatment space.
Congratulations to anyone who happened to own Islet Sciences Inc. (OTCMKTS:ISLT) before Friday's close. ISLT shares shot out of the gate on Monday morning, end the day with a 250% gain... proving penny stocks can and do pay off when the timing and story is right. If you're serious about tapping into the next era of diabetes treatments, though, then you may want to lock in what you can while you can with Islet Sciences and then take a closer look at Pharmacyte Biotech Inc. (OTCMKTS:PMCB). It's developing a novel diabetes therapy of its own, and could change the way we think about treating the dreaded disease.
Don't look for any particular reason something news-related lit a fire under ISLT on Monday - you won't find it. Sometimes penny stocks just strike the right cord with the right group of people and develop a life of their own.
That's not to take away from the work Islet Sciences has done. It's work in the area of creating immune-modulating drugs that protect insulin-producing beta-cells from cytokines responsible for cell destruction has been eye-opening, and shows promise. Specifically, Islet Sciences Inc. has found that microencapsulated -- protected -- porcine islets injected into the abdominal cavity can effectively serve as a transplanted pancreas for diabetic patients. What's not clear is the longevity of the encapsulated cells. In trials this far, 85% of transplantees remained insulin-independent at the one-year mark, but a 15% attrition rate in just the first year doesn't necessarily bode well as a long-term fix given the surgery involved.
It's akin to an approach Pharmacyte Biotech is taking to treat diabetes as well, but perhaps with a little more promise.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed in the leg near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
The key is the polymer used to encapsulate living cells.
The manufacturing process begins with the mix of live cells (insulin-producing Melligen cells, in this case) and a polymer which are sent through a droplet-forming machine and into a small vat of another proprietary polymer. When the two polymers join, a membrane is formed, with the living cells inside of it. This shell keeps the cells inside, yet lets insulin out, while allowing nutrients in, and waste out. Most important though, the shell keeps the body's own immune system from killing these cells.... something most previous encapsulation approaches didn't do. A handful of these pinhead-sized capsules containing Melligen cells can replace the insulin-producing function of the pancreas from some other site in the body.
Cell-in-a-Box as a therapy for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials
It's a major leap forward for diabetics - an encapsulation biotechnology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials.
And yes, though still in preclinical testing, the premise has been proven safe.
The work will be worth the effort. The diabetes treatment market is worth an estimated $7 billion per year, and Cell-in-a-Box is effectively a cure for it that abates the need for needles. In the meantime, investors are apt to reward the stock as the company achieves critical milestones en route to the endzone.
None of this is to take away from what Islet Sciences has done, or any other penny stocks of companies working on diabetes therapies. All that other work, however, underscores just how game-changing PMCB could be in the world of diabetes.
$PMCB If You Like Islet Sciences, You'll Love Pharmacyte Biotech
Islet Sciences Inc. (OTCMKTS:ISLT) shares were all the rage on Monday, but Pharmacyte Biotech Inc. (OTCMKTS:PMCB) remains one of the market's most compelling penny stocks in the diabetes treatment space.
Congratulations to anyone who happened to own Islet Sciences Inc. (OTCMKTS:ISLT) before Friday's close. ISLT shares shot out of the gate on Monday morning, end the day with a 250% gain... proving penny stocks can and do pay off when the timing and story is right. If you're serious about tapping into the next era of diabetes treatments, though, then you may want to lock in what you can while you can with Islet Sciences and then take a closer look at Pharmacyte Biotech Inc. (OTCMKTS:PMCB). It's developing a novel diabetes therapy of its own, and could change the way we think about treating the dreaded disease.
Don't look for any particular reason something news-related lit a fire under ISLT on Monday - you won't find it. Sometimes penny stocks just strike the right cord with the right group of people and develop a life of their own.
That's not to take away from the work Islet Sciences has done. It's work in the area of creating immune-modulating drugs that protect insulin-producing beta-cells from cytokines responsible for cell destruction has been eye-opening, and shows promise. Specifically, Islet Sciences Inc. has found that microencapsulated -- protected -- porcine islets injected into the abdominal cavity can effectively serve as a transplanted pancreas for diabetic patients. What's not clear is the longevity of the encapsulated cells. In trials this far, 85% of transplantees remained insulin-independent at the one-year mark, but a 15% attrition rate in just the first year doesn't necessarily bode well as a long-term fix given the surgery involved.
It's akin to an approach Pharmacyte Biotech is taking to treat diabetes as well, but perhaps with a little more promise.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed in the leg near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
The key is the polymer used to encapsulate living cells.
The manufacturing process begins with the mix of live cells (insulin-producing Melligen cells, in this case) and a polymer which are sent through a droplet-forming machine and into a small vat of another proprietary polymer. When the two polymers join, a membrane is formed, with the living cells inside of it. This shell keeps the cells inside, yet lets insulin out, while allowing nutrients in, and waste out. Most important though, the shell keeps the body's own immune system from killing these cells.... something most previous encapsulation approaches didn't do. A handful of these pinhead-sized capsules containing Melligen cells can replace the insulin-producing function of the pancreas from some other site in the body.
Cell-in-a-Box as a therapy for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials
It's a major leap forward for diabetics - an encapsulation biotechnology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical testing phase, although it was recently determined to be safe as a means of treating type 1 diabetes by the University of Veterinary Medicine Vienna. Based on the results witnesses in the preliminary studies at the university, the company aims to move forward with plans that will ultimately result in human trials.
And yes, though still in preclinical testing, the premise has been proven safe.
The work will be worth the effort. The diabetes treatment market is worth an estimated $7 billion per year, and Cell-in-a-Box is effectively a cure for it that abates the need for needles. In the meantime, investors are apt to reward the stock as the company achieves critical milestones en route to the endzone.
None of this is to take away from what Islet Sciences has done, or any other penny stocks of companies working on diabetes therapies. All that other work, however, underscores just how game-changing PMCB could be in the world of diabetes.
$PMCB PharmaCyte Biotech (PMCB) is locked and loaded -- money-wise -- for a while, funded to begin the next phase of its pancreatic cancer trial. The press release was posted this morning -- PMCB pocketed $1 million via the sale of equity, bringing its cash balance up to $3 million. That should get the company pretty far down the R&D road.
As impressive as garnering a million bucks worth of funding in this environment is, I think the real story with PMCB is the chart itself.
Some of you may recall we figured the sharp, high volume selloff from December 31st was a capitulation, and the beginning of a rebound move. We still have every reason to think that. Although the stock stalled as it approached the 50-day moving average line (purple), the 20-day line (blue) has since stepped up as a floor. It even looks like the bulls are trying to use the 20-day moving average line as something of a springboard. One good push above $0.08 could ignite another round of buying.
$PMCB PharmaCyte Biotech (PMCB) is locked and loaded -- money-wise -- for a while, funded to begin the next phase of its pancreatic cancer trial. The press release was posted this morning -- PMCB pocketed $1 million via the sale of equity, bringing its cash balance up to $3 million. That should get the company pretty far down the R&D road.
As impressive as garnering a million bucks worth of funding in this environment is, I think the real story with PMCB is the chart itself.
Some of you may recall we figured the sharp, high volume selloff from December 31st was a capitulation, and the beginning of a rebound move. We still have every reason to think that. Although the stock stalled as it approached the 50-day moving average line (purple), the 20-day line (blue) has since stepped up as a floor. It even looks like the bulls are trying to use the 20-day moving average line as something of a springboard. One good push above $0.08 could ignite another round of buying.
$PMCB PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial
SILVER SPRING, Md., Jan. 14, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial and to continue its work in both pancreatic cancer and diabetes.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We have a lot of work ahead of us this year at PharmaCyte. With the recently announced private placement of just over $1 million, we have not only increased our cash on hand to over $3.0 million but have increased our leverage in the capital markets. What is mission critical for PharmaCyte is getting into a pancreatic cancer clinical trial and producing the data that is necessary for us to approach the FDA. We have every expectation that will occur this year.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
$PMCB PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial
SILVER SPRING, Md., Jan. 14, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial and to continue its work in both pancreatic cancer and diabetes.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We have a lot of work ahead of us this year at PharmaCyte. With the recently announced private placement of just over $1 million, we have not only increased our cash on hand to over $3.0 million but have increased our leverage in the capital markets. What is mission critical for PharmaCyte is getting into a pancreatic cancer clinical trial and producing the data that is necessary for us to approach the FDA. We have every expectation that will occur this year.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB Cell Encapsulation for Drug Delivery & Disease Treatment
http://www.pharmacytebiotech.com/wp-content/uploads/2015/01/Cellular-Microencapsulation.pdf
Go $PMCB
$PMCB Cell Encapsulation for Drug Delivery & Disease Treatment
http://www.pharmacytebiotech.com/wp-content/uploads/2015/01/Cellular-Microencapsulation.pdf
Go $PMCB
$DCAC ~ Daniels Corporate Advisory Co Inc due diligence report
$DCAC recent news/filings
## source: finance.yahoo.com
Fri, 24 Jul 2015 17:04:07 GMT ~ DANIELS CORPORATE ADVISORY COMPANY, INC. Financials
read full: http://finance.yahoo.com/q/is?s=dcac
*********************************************************
Tue, 21 Jul 2015 14:00:00 GMT ~ Daniels Corporate Advisory Company, Inc. Creates a Food & Beverage Acquisition Group
[GlobeNewswire] - NEW YORK -- Daniels Corporate Advisory Co. Inc. (OTCQB:DCAC), a Corporate Strategy Consulting Company, announces the expansion of its own business strategy model with their newly created subsidiary, "Daniels ...
read full: http://finance.yahoo.com/news/daniels-corporate-advisory-company-inc-140000850.html
*********************************************************
Mon, 20 Jul 2015 14:04:04 GMT ~ DANIELS CORPORATE ADVISORY COMPANY, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/150720/dcac10-q.html
*********************************************************
Tue, 09 Jun 2015 19:58:49 GMT ~ DANIELS CORPORATE ADVISORY COMPANY, INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/150609/dcac8-k.html
*********************************************************
Tue, 19 May 2015 13:00:00 GMT ~ "New To The Street" Announces Line-Up for Next 2 Airings in Top 5 Markets
[Marketwired] - "New To The Street" will be broadcasting its latest show in the top 5 markets, New York, LA, Philadelphia, Boston and Miami, the week of May 26, 2015, reaching 75 million households.
read full: http://finance.yahoo.com/news/street-announces-line-next-2-130000262.html
*********************************************************
$DCAC charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$DCAC company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/DCAC/company-info
Ticker: $DCAC
OTC Market Place: OTCQB
CIK code: 0001498291
Company name: Daniels Corporate Advisory Co Inc
Company website: http://www.danielscorporateadvisoryco.com
Incorporated In: NV, USA
Business Description: Founded in 2002, Daniels (OTC: DCAC) is a corporate strategy firm servicing the myriad needs of small, growing public and private companies through customized financiawl, operational and business strategy initiatives. From securing growth capital to the placement of senior-level team members, Daniels provides clients with unique and appropriate strategies designed to incubate and accelerate their growth in new or existing niche markets. These strategies include joint-ventures, marketing opportunities, partnerships, and potential acquisitions. Whether generic or acquisitive in nature, the optimum deal structure to accelerate growth is designed to limit the amount of time necessary for the client to achieve the requirements to list on a major US Stock Exchange (American/Small Cap NASDAQ). Daniels strives to complete the process within 14 to 24 months following its initial engagement with the client. ApproachDaniels is backed by the belief that proven skills sets and a viable, creative business model have a way of selling themselves and when implemented correctly, can be the best catalyst for growth of a small company. In this effort, Daniels incubates new and existing companies as subsidiaries, including creating world-class personnel teams and the best go-to-market strategies, as well as providing growth capital. Daniels finances their growth with capital raised from the sale of Daniels registered common stock until the time when the incubated company is viable, profitable, revenue-generating, and entirely self-sufficient. Once viable, the subsidiary is spun-off to the independent contractors instrumental in its operation and expansion, as well as to the shareholder base of Daniels Corporate Advisory Co. Inc. and Daniels itself.The spin-off is necessary -allowing for the monetization of consulting time and the recapture of the equity cost to the Parent Company (Daniels) for funding the subsidiary with common stock during its incubation period. The recapture of labor and capital costs, plus a significant rate of return on investment, are achievable primarily through a simple change in valuation method ? from that of a private company to one of a public company with incubation created profits at a public market valuations.During incubation, progress throughout every phase of the company's development is released to the public and to investors. This consistent communication to the public and enhanced visibility in the market under the Daniels Corporate Advisory stock symbol builds a foundation for the company with not only retail and institutional investors, many of whom will be interested in ownership equity in the company once it's spun-off, but also customers and/or partners whom will want to buy the company's products and/or services resulting in increased sales and earnings.Daniels' Business Model achieves milestones necessary with current clients to attract new clients -those with quality start-up ideas and/or new products. We limit overall risk associated with start-ups by selecting candidates with new products and services that are already part of an existing product mix that is successful in its own right. For example, a foreign product manufacturer, successful in its own country, has the ability to launch that product in the United States through a Sales Agency Relationship with Daniels.HIGHLIGHTS - Daniels Provides: - Growth Acceleration Strategies for the Start-up and Early-Stage Development Private and Public Companies- Well focused Business Models Designed to Achieve Expansion Initiatives - Cost-Effective, Independent Contractor Talent Pool for all Management Disciplines- Visionary Team Members with Management and Operational Expertise- Implementation Capital Available During Incubation and IPO Stage.- Incubated Companies valued as a Public Company with Stock Market ValuationsLess >>
$DCAC share structure
## source: otcmarkets.com
Market Value: $1,361,798 a/o Aug 14, 2015
Shares Outstanding: 28,078,319 a/o Jul 15, 2015
Float: 10,081,712 a/o Feb 26, 2015
Authorized Shares: 750,000,000 a/o Feb 26, 2015
Par Value: 0.001
$DCAC extra dd links
Company name: Daniels Corporate Advisory Co Inc
Company website: http://www.danielscorporateadvisoryco.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DCAC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DCAC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DCAC+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/news - http://finance.yahoo.com/q/h?s=DCAC+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DCAC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DCAC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DCAC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Daniels+Corporate+Advisory+Co+Inc&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Daniels+Corporate+Advisory+Co+Inc
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Daniels+Corporate+Advisory+Co+Inc&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.danielscorporateadvisoryco.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.danielscorporateadvisoryco.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.danielscorporateadvisoryco.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DCAC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001498291&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DCAC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DCAC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DCAC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DCAC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DCAC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DCAC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DCAC+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DCAC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DCAC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DCAC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DCAC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DCAC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DCAC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DCAC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DCAC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DCAC
$DCAC ~ Daniels Corporate Advisory Co Inc due diligence report
$DCAC recent news/filings
## source: finance.yahoo.com
Fri, 24 Jul 2015 17:04:07 GMT ~ DANIELS CORPORATE ADVISORY COMPANY, INC. Financials
read full: http://finance.yahoo.com/q/is?s=dcac
*********************************************************
Tue, 21 Jul 2015 14:00:00 GMT ~ Daniels Corporate Advisory Company, Inc. Creates a Food & Beverage Acquisition Group
[GlobeNewswire] - NEW YORK -- Daniels Corporate Advisory Co. Inc. (OTCQB:DCAC), a Corporate Strategy Consulting Company, announces the expansion of its own business strategy model with their newly created subsidiary, "Daniels ...
read full: http://finance.yahoo.com/news/daniels-corporate-advisory-company-inc-140000850.html
*********************************************************
Mon, 20 Jul 2015 14:04:04 GMT ~ DANIELS CORPORATE ADVISORY COMPANY, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/150720/dcac10-q.html
*********************************************************
Tue, 09 Jun 2015 19:58:49 GMT ~ DANIELS CORPORATE ADVISORY COMPANY, INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/150609/dcac8-k.html
*********************************************************
Tue, 19 May 2015 13:00:00 GMT ~ "New To The Street" Announces Line-Up for Next 2 Airings in Top 5 Markets
[Marketwired] - "New To The Street" will be broadcasting its latest show in the top 5 markets, New York, LA, Philadelphia, Boston and Miami, the week of May 26, 2015, reaching 75 million households.
read full: http://finance.yahoo.com/news/street-announces-line-next-2-130000262.html
*********************************************************
$DCAC charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$DCAC company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/DCAC/company-info
Ticker: $DCAC
OTC Market Place: OTCQB
CIK code: 0001498291
Company name: Daniels Corporate Advisory Co Inc
Company website: http://www.danielscorporateadvisoryco.com
Incorporated In: NV, USA
Business Description: Founded in 2002, Daniels (OTC: DCAC) is a corporate strategy firm servicing the myriad needs of small, growing public and private companies through customized financiawl, operational and business strategy initiatives. From securing growth capital to the placement of senior-level team members, Daniels provides clients with unique and appropriate strategies designed to incubate and accelerate their growth in new or existing niche markets. These strategies include joint-ventures, marketing opportunities, partnerships, and potential acquisitions. Whether generic or acquisitive in nature, the optimum deal structure to accelerate growth is designed to limit the amount of time necessary for the client to achieve the requirements to list on a major US Stock Exchange (American/Small Cap NASDAQ). Daniels strives to complete the process within 14 to 24 months following its initial engagement with the client. ApproachDaniels is backed by the belief that proven skills sets and a viable, creative business model have a way of selling themselves and when implemented correctly, can be the best catalyst for growth of a small company. In this effort, Daniels incubates new and existing companies as subsidiaries, including creating world-class personnel teams and the best go-to-market strategies, as well as providing growth capital. Daniels finances their growth with capital raised from the sale of Daniels registered common stock until the time when the incubated company is viable, profitable, revenue-generating, and entirely self-sufficient. Once viable, the subsidiary is spun-off to the independent contractors instrumental in its operation and expansion, as well as to the shareholder base of Daniels Corporate Advisory Co. Inc. and Daniels itself.The spin-off is necessary -allowing for the monetization of consulting time and the recapture of the equity cost to the Parent Company (Daniels) for funding the subsidiary with common stock during its incubation period. The recapture of labor and capital costs, plus a significant rate of return on investment, are achievable primarily through a simple change in valuation method ? from that of a private company to one of a public company with incubation created profits at a public market valuations.During incubation, progress throughout every phase of the company's development is released to the public and to investors. This consistent communication to the public and enhanced visibility in the market under the Daniels Corporate Advisory stock symbol builds a foundation for the company with not only retail and institutional investors, many of whom will be interested in ownership equity in the company once it's spun-off, but also customers and/or partners whom will want to buy the company's products and/or services resulting in increased sales and earnings.Daniels' Business Model achieves milestones necessary with current clients to attract new clients -those with quality start-up ideas and/or new products. We limit overall risk associated with start-ups by selecting candidates with new products and services that are already part of an existing product mix that is successful in its own right. For example, a foreign product manufacturer, successful in its own country, has the ability to launch that product in the United States through a Sales Agency Relationship with Daniels.HIGHLIGHTS - Daniels Provides: - Growth Acceleration Strategies for the Start-up and Early-Stage Development Private and Public Companies- Well focused Business Models Designed to Achieve Expansion Initiatives - Cost-Effective, Independent Contractor Talent Pool for all Management Disciplines- Visionary Team Members with Management and Operational Expertise- Implementation Capital Available During Incubation and IPO Stage.- Incubated Companies valued as a Public Company with Stock Market ValuationsLess >>
$DCAC share structure
## source: otcmarkets.com
Market Value: $1,361,798 a/o Aug 14, 2015
Shares Outstanding: 28,078,319 a/o Jul 15, 2015
Float: 10,081,712 a/o Feb 26, 2015
Authorized Shares: 750,000,000 a/o Feb 26, 2015
Par Value: 0.001
$DCAC extra dd links
Company name: Daniels Corporate Advisory Co Inc
Company website: http://www.danielscorporateadvisoryco.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DCAC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DCAC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DCAC+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/news - http://finance.yahoo.com/q/h?s=DCAC+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DCAC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DCAC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DCAC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Daniels+Corporate+Advisory+Co+Inc&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Daniels+Corporate+Advisory+Co+Inc
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Daniels+Corporate+Advisory+Co+Inc&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.danielscorporateadvisoryco.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.danielscorporateadvisoryco.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.danielscorporateadvisoryco.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DCAC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001498291&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DCAC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DCAC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DCAC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DCAC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DCAC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DCAC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DCAC+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DCAC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DCAC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DCAC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DCAC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DCAC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DCAC/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DCAC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DCAC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DCAC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DCAC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DCAC